Advertisement
Research Article| Volume 20, ISSUE 1, P63-67, February 1999

Treatment of chronic dysimmune polyneuropathies

      Abstract

      Chronic dysimmune neuropathies are less common than Guillain–Barré syndrome (GBS). They mainly comprise chronic idiopathic demyelinating polyneuropathy (CIDP), multifocal motor neuropathy with persistent conduction blocks (MMNCB) and polyneuropathy associated with monoclonal gammopathy. However, as GBS, they are considered to be immune-mediated disorders and they may respond to various immunosuppressive treatments, such as corticosteroids, plasma exchanges (PE) or intravenous immunoglobulins (IVIg). The first step is to characterize these neuropathies on clinical, electrophysiological and sometimes immunochemical criteria, because the response to treatment may be different according to the type of neuropathy. For example, polyneuropathy associated with IgM monoclonal gammopathy does not respond to steroids and MMNCB may worsen under PE, while CIDP may respond either to steroids, PE or IVIg. The second step is to choose the type and the regimen of the treatment. Some neurological conditions may require only short-term therapy, for example in relapsing CIDP, whereas other conditions may require long-term therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Dyck PJ, O'Brien PC, Oviatt KD et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136–141

      2. Molenaar DSM, van Doorn PA, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 1997;62:388–390

      3. Dyck PJ, Daube J, O'Brien PC et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461–465

      4. Hahn AF, Bolton CF, Pillay N et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 1996;119:1055–1066

      5. van Doorn PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 1991;48:217–220

      6. Vermeulen M, van Doorn PA, Brand A, Strengers PFW, Jennekens FGI, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, study. J Neurol Neurosurg Psychiatry 1993;56:36–39

      7. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067–1077

      8. Dyck PJ, Litchy WJ, Kratz KM et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 1994;36:838–845

      9. Lewis RA, Summer AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982;32:958–964

      10. Bouche P, Moulonguet A, Younes-Chennoufi A et al. Multifocal motor neuropathy associated with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995;59:38–44

      11. Azulay JP, Blin O, Pouget J et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994;44:429–432

      12. Van den Berg LH, Kerkhoff H, Oey PI et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double-blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1995;59:248–252

      13. Oksenhendler E, Chevret S, Léger JM, Louboutin JP, Bussel A, Brouet JC for the IgM-associated polyneuropathy study group. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neurosurg Psychiatry 1995;59:243–47

      14. Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Ann Neurol 1995;45:1577–80

      15. Notermans NC, Lokhorst HM, Franssen H et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology 1996;47:1227–1233

      16. Léger JM, Ben Younes-Chennoufi A, Chassande B et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 1994;57 Suppl:46–49

      17. Dalakas MC, Richard HQ, Farrer RG et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40:792–795

      18. Mariette X, Chastang C, Clavelou P et al. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 1997;63:28–34

      19. Dyck PJ, Low PA, Windebank AJ et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991;325:1482–1486